GLOBAL 2025 VISION
Daewoong Pharmaceutical currently has the most overseas corporations and branches (8) among domestic pharmaceutical companies, and has constructed various collaboration infrastructure including research, development, manufacturing, sales, etc. with clients to supply products desired by local markets to strengthen its local competitiveness.
Furthermore, we will ceaselessly search for, hire and foster outstanding human resources from around the world and help them contribute to the development of local pharmaceutical industries to provide the foundation for them to grow into global healthcare companies.
We will continuously pursue business structure and infrastructure innovation to become a company that researches, develops and distributes products desired by the market through the collaboration of local customers and employees, while contributing to the development of the local industry.
Strengthening market competitiveness
We will expand the self-management infrastructure of overseas corporation in order to procure business sustainability, while constructing a collaborative network with multiple partners such as local manufacturers, research centers and pharmaceutical companies, while the HQ directly manages core clients to continuously expand its market dominance.
Fostering global talents
We will ceaselessly find and support outstanding talents with the will and passion for global collaboration including domestic and foreign medical scientists, researchers and international students, and actively recruit human resources who wish to grow continuously with the company and help cultivate them to empower them to develop the global pharmaceutical industry.
- Branch Operations
in Asia & US
- R&D Centers
- Daewoong America Daewoong America Inc.
Address 1 Church St. STE 103, Rockville, MD 20850, USA.
Daewoong Pharmaceutical has continued exchange with multiple local research groups to enter the US market since 2006 and it established a local corporation in Maryland in December 2009. It plans to gain a foothold in the US market with products such as its flagship product URSA, as well as generics and improved new oral drugs. In particular, as launching in the US market nears, we will engage in ongoing C&D activities and implement new pharmaceutical technologies and export new drugs/technologies to continue to lead R&D globalization.